Leveraging intellectual property as bifunctional protein degraders enter clinical trials

The field of protein degraders is at an inflection point as more degraders enter the clinical space. Evaluating the patent filing activity will play a critical role in the ability to managing opportunities for licensing and partnerships.

Related Keywords

Michigan ,United States ,Oerth Bio ,Genentech ,University Of Dundee ,Pfizer ,Dana Farber Cancer Institute ,University Of Michigan ,Patent Cooperation Treaty ,Nature Reviews Clinical Oncology ,Targeted Protein ,Law Business Researchcompany Number , ,